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Abstract
Genetically modified adipose tissue derived mesenchymal stromal cells (hAMSCs) with tumor homing capacity have been
proposed for localized therapy of chemo- and radiotherapy resistant glioblastomas. We demonstrate an effective procedure
to optimize glioblastoma therapy based on the use of genetically modified hAMSCs and in vivo non invasive monitoring of
tumor and therapeutic cells. Glioblastoma U87 cells expressing Photinus pyralis luciferase (Pluc) were implanted in
combination with hAMSCs expressing a trifunctional Renilla reniformis luciferase-red fluorescent protein-thymidine kinase
reporter in the brains of SCID mice that were subsequently treated with ganciclovir (GCV). The resulting optimized therapy
was effective and monitoring of tumor cells by bioluminescence imaging (BLI) showed that after 49 days GCV treatment
reduced significantly the hAMSC treated tumors; by a factor of 10
4 relative to controls. Using a Pluc reporter regulated by an
endothelial specific promoter and in vivo BLI to image hAMSC differentiation we gained insight on the therapeutic
mechanism. Implanted hAMSCs homed to tumor vessels, where they differentiated to endothelial cells. We propose that the
tumor killing efficiency of genetically modified hAMSCs results from their association with the tumor vascular system and
should be useful vehicles to deliver localized therapy to glioblastoma surgical borders following tumor resection.
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Introduction
Glioblastoma multiforme (GBM), a brain tumor with high
morbidity and mortality, accounts for the highest proportion of
deaths from brain tumors [1]. The average survival of patients
diagnosed with GBM is 14 months, and only 2% of the patients
survive up to 3 years [2,3]. Current treatment protocols for GBM
are ineffective due to its invasiveness, which precludes complete
surgical removal and to persistence of radiation and chemotherapy
resistant cells after therapy. A promising approach based on the
use of cellular vehicles to deliver localized treatment targeting the
primary tumor mass has been proposed [4]. Different types of stem
cells have shown therapeutic potential against glioblastomas
[5,6,7,8]. However, due to their tumor homing capacity and ease
of genetic manipulation bone marrow mesenchymal stromal cells
appear as particularly promising therapeutic vehicles [9]. Human
mesenchymal stromal cells are abundant and easily extracted from
adipose tissue and have properties similar to those of their bone
marrow counterparts: ease of expansion from autologous tissue
[10,11,12], demonstrated homing capacity towards tumors
[13,14,15] and participation in the stroma of different types of
tumors [16], ease of genetic manipulation [17], capacity to inhibit
immune and inflammatory reactions [18] and genetic stability, not
generating tumors when implanted during long periods of time
[19]. Recently, a rat C6 glioblastoma tumor model was
successfully treated with human adipose tissue mesenchymal
stromal cells (hAMSCs) modified to express cytosine deamina-
se:uracil phosphoribosyltransferase [20].
Targeted cytotoxicity strategies, developed during the last 20
years for gene therapy, are based on the activation of a
systemically delivered low toxicity prodrug to a cytotoxic agent
in the vicinity of tumors, mediated by the action of a specific
activating enzyme previously introduced in the therapy vehicle
[21]. The delivery of cytotoxicity in the vicinity of a tumor has the
advantage of avoiding systemic toxicity. The thymidine kinase
encoded by herpes simplex virus (HSV-TK) was used in the first
cell suicide gene therapy proof of principle and still is one of the
most widely used systems in clinical and experimental applications
[22,23]. This cytotoxic system has been applied to the treatment of
gliomas with significant increases in survival [24]. HSV-TK is
responsible for the conversion of deoxythimidine to deoxythyimi-
dine monophosphate in infected cells. Due to its relaxed
specificity, this enzyme can phosphorylate a variety of nucleotide
analogs including ganciclovir (GCV), a 29-deoxiguanosine analog
[25]. The incorporation of phosphorylated GCV in DNA results
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[2,13,14,26]. Transfer of dying cell components through gap
junctions and diffusion results in the killing of neighboring cells,
with amplification of the therapeutic effect.
In the current work, we develop and demonstrate an efficient
therapeutic strategy model against a Photynus pyralis luciferase (Pluc)
and enhanced green protein (eGFP) expressing U87 glioblastoma
model in SCID mice, using hAMSCs genetically modified to
express a tri-functional reporter comprising Renilla reniformis
luciferase (Rluc), red fluorescent protein (RFP) and a truncated
version of HSV-TK (tTK). The latter enzyme has a 30 fold higher
activity than wild type HSV-TK [26,27]. By taking advantage of
bioluminescence imaging (BLI) to noninvasively monitor luciferase
expressing tumor and therapeutic cells, we were able to fine tune
and evaluate the therapeutic process in real time. In addition, the
imaging platform allowed us to observe the behavior of
therapeutic hAMSCs, offering insight into the therapeutic
mechanism.
Results
Photoprotein expressing hAMSC and U87 cells
To noninvasively monitor the behavior of tumor and thera-
peutic cells during therapy, hAMSCs were genetically modified by
transduction with a lentiviral vectors for stable expression of a tri-
functional chimeric reporter including Rluc, RFP and tTK
activities, to generate Rluc-R-tTK-hAMSC or ‘‘therapeutic
vehicles’’. Human glioblastoma U87 tumor cells were also
genetically modified by transduction with a lentiviral vector for
stable expression of a chimeric reporter with Pluc and eGFP
activities, to generate ‘‘Pluc-G-U87’’ tumor cells. This strategy
allowed independent imaging of therapeutic and tumor cells using
non-cross-reacting luciferase substrates, coelenterazin and lucifer-
in, respectively. In addition, the inclusion of two different
fluorescent protein reporters, allowed selection of labeled cells by
FACS, and detection of therapeutic and tumor cells by
fluorescence confocal microscopy of tissue sections. Lentiviral
transduction did not change doubling time or immunophenotype
of Rluc-R-tTK-hAMSCs, as determined by flow cytometry
analysis of hAMSC markers (Fig. S1).
Bystander killing of Pluc-G-U87 glioblastoma cells by
Rluc-R-tTK-hAMSC in vitro
To demonstrate tTK gene was functional in the genetically
modified therapeutic vehicles, replicate cultures of Pluc-G-U87,
hAMSCs and Rluc-R-tTK-hAMSCs seeded in tissue culture
plates were treated with ganciclovir (GCV) or PBS and cell
survival assessed using the CellTiter 96 Aqueous One Solution
Cell Proliferation Assay. Treatment with GCV had no effect on
survival of Pluc-G-U87 alone (Fig. 1A) or on wt hAMSCs lacking
the tTK gene (Fig. 1B). What is more, in the absence of GCV the
growth pattern of hAMSCs was similar regardless of whether they
expressed or not the tTK gene (Fig. S1B), indicating that the tTK
gene had no negative effect on cell proliferation. However, as
expected, GCV treatment did exert a strong cytotoxic effect,
proportional to its concentration, on tTK expressing hAMSCs
(Fig. S2) (*P,0,05).
In a different experiment to assess bystander effect, cocultures of
luciferase expressing therapeutic and tumor cells in different
proportions (1:20, 2:20, 4:20) Rluc-R-tTK-hAMSC:Pluc-G-U87
were treated with GCV (4 mg/ml) or PBS. In these experiments,
where tumor and therapeutic cells express luciferase reporters,
survival of Pluc-G-U87 cells was determined by bioluminescence.
As shown in Fig. 1C, viability of Pluc-G-U87 cells in the
presence of GCV was inversely proportional to the ratio of
therapeutic to tumor cells (88%, 93%, 94% killing for 1:20, 2:20,
4:20 Rluc-R-tTK-hAMSC:Pluc-G-U87), but was not affected by
treatment with PBS (*p,0,05; **p.0,01).
Detection sensitivity of Pluc-G-U87 and Rluc-R-tTK-
hAMSC in vivo
Skull bone and intervening brain tissue in live animals reduce
the efficiency with which light photons reach the video camera
detector used for BLI. To establish a correlation between light
measurements and cell number, predetermined numbers of Pluc-
G-U87 and Rluc-R-tTK-hAMSC were implanted in the brain of
live mice at specific coordinates (0,6 mm posterior, 2 mm lateral
and 2,75 mm depth respect Bregma) later used for experiments,
and immediately after implantation imaged by BLI after
administration of the corresponding luciferase substrate, luciferin
or coelenterazine. The number of recorded photon events (PHCs)
was extracted from recorded images and plotted, after background
subtraction, versus the number of inoculated cells. As shown in
Fig. 2, detection sensitivity (slope of the correlation curve) was
similar for both cell types and there was a good linear correlation
between the amount of light produced and the number of cells
implanted, 34,2 PHCs/cell, R
2=0,994 and 20,64 PHCs/cell,
R
2=0,974 for Pluc-G-U87 and Rluc-R-tTK-hAMSC, respective-
ly.
Optimal Rluc-R-tTK-hAMSC dose for in vivo bystander
effect
Mixed cell populations comprising Pluc-G-U87 cells (4610
4)
and different proportions of Rluc-R-tTK-hAMSCs, (1:1, 1:2, 1:4)
respectively, were injected in the brain of SCID mice at the
previously indicated coordinates (n=15) to establish the best
proportion of therapeutic to tumor cells. Two control groups
(n=10), were also included, one of them consisting of mice
injected with 4610
4 Pluc-G-U87 cells only, that was treated with
GCV; and the other consisting of mice injected with the same
number of Pluc-G-U87 cells in a 1:1 proportion with Rluc-R-tTK-
hAMSCs, that was treated with PBS. Imaging of Rluc activity was
used to monitor implantation of Rluc-R-tTK-hAMSCs. Beginning
six days after the cell implantation (T=0), and during a 35 day
period, the inoculated mice were treated daily by i.p. administra-
tion of GCV or PBS, as indicated. Light emission by Pluc
luciferase was monitored by BLI from the beginning of GCV
treatment and every week thereafter. Image sequences of tumors
were used to monitor tumor growth during the experiment.
Analysis of photons captured in all images and statistical
evaluation showed (Fig. 3A and B) that mixed cell tumors (1:1)
treated with PBS grew at a similar rate than control tumors treated
with GCV but without therapeutic cells (p.0,05). However,
treatment with GCV of tumors bearing therapeutic cells inhibited
tumor growth relative to controls. Although a trend in tumor
growth inhibition appears from the start of the GCV treatment, a
clear inhibition of tumor growth was apparent by day 21 and was
evident by day 35 of GCV treatment in all the therapeutic cell
proportions tested. The therapeutic effect directly correlated with
the proportion of therapeutic cells used, being 1:4 the most
effective cell dose, and in this group of mice, by the end of the
experiment (T=35) the amount of light produced by the tumors
was 0,14% of the light produced by those in the control group
(Pluc-G-U87 only) (p,0,05). Analysis comparing tumor size at the
start (T=0) and end (T=35) of treatments shows a significant size
reduction (p,0,05) for all the tumors treated with therapeutic cells
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cells were omitted. In the 1:4+GCV group, only 3% of light
produced by tumor cells at T=0 persisted at the inoculation sites
following GCV treatment. Fig. 3C shows representative images
from single animals from the groups (n=5) treated with GCV and
with or without therapeutic cells (1:4+GCV).
In vivo Rluc-R-tTK-hAMSC mediated bystander
glioblastoma therapy
A group of 24, 6 week old SCID mice was stereotactically
inoculated at the previously indicated coordinates with either a
mixture of 4610
4 Pluc-G-U87 cells and 1.6610
5 Rluc-R-tTK-
hAMSCs (n=16) or with 4610
4 Pluc-G-U87 tumor cells only
(n=8). Six days post implantation (T=0), the mice were imaged
by BLI to monitor Pluc activity from the Pluc-G-U87 tumors and
Rluc activity from Rluc-R-tTK-hAMSC cells, and a treatment
regime was initiated as described in the diagram of Fig. 4A. In
brief, one half of the mice implanted with Pluc-G-U87 and Rluc-
R-tTK-hAMSC cells received GCV, while the other half received
the same volume of PBS. Mice implanted with only Pluc-G-U87
cells also received GCV. Treatment was administered during two
3 week periods, separated by a one week rest period. At day 49 all
the control mice were sacrificed, as required by the animal welfare
protocol.
Bioluminescence imaging (BLI) was used to monitor tumor
development during the experiment. As indicated in Fig. 4B,
showing representative images from single animals in each of the
experimental groups, treatment of mixed cell tumors with PBS, or
of control tumors (lacking therapeutic cells) with GCV had no
inhibitory effect on tumor growth, and light production by Pluc-G-
U87 cells progressively increased up to the end of the experiment.
However, treatment of mixed cell tumors with GCV resulted in
the progressive reduction of light produced by Pluc-G-U87 cells up
to the end of the experiment, when light from Pluc-G-U87 cells
reached background level (Fig S3). Quantitative evaluation of
therapeutic effect is shown by plots of total light events recorded in
images from the tumor areas vs. time (Fig. 4D). This analysis
shows that the amount of light produced by tumors containing
therapeutic cells that were treated with GCV, by the end of the
experiment was 10
4 times lower than that produced by control
tumors treated with GCV or by tumors with therapeutic cells
treated with PBS (p,0,05). Moreover, by the end of the
experiment, light produced by tumors treated with therapeutic
cells plus GCV was only 0,12% the amount of light produced by
the same tumors at T=0 (6 days after cell implantation) (n=8).
Figure 1. Sensitivity of PLuc-G-U87 cells, Rluc-R-tTK-hAMSC and hAMSC and co-cultures comprising different proportions of Rluc-
R-tTK-hAMSCs and PLuc-U87 cells to GCV. Cells were grown during the indicated times and treated with either GCV (4 mg/ml) or PBS, as
indicated. Number of viable cells was evaluated spectrophotometrically by standard 3-(4-5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium salt (MTS assay) (A, B), or by BLI (C), and expressed as percentage increase relative to cell number at day 0. Histograms
show mean 6 SEM, *p,0.05, **p,0.01 n=4 for each group.
doi:10.1371/journal.pone.0035148.g001
Figure 2. In vivo BLI sensitivity. The indicated numbers of Pluc-G-U87 (A) and Rluc-R-tTK-hAMSC cells (B) were stereotactically implanted, at the
same coordinates later used for experiments in the brain of immunosupressed mice and imaged after luciferin or coelenterazine substrate
administration, respectively. The number of light events (PHCs) recorded from the mice brains was plotted, after background subtraction, versus the
number of implanted cells. R
2 correlation coefficient. Data are presented as mean 6SEM, n=4 in each group.
doi:10.1371/journal.pone.0035148.g002
Bioluminiscence Imaging for Glioma Cell Therapy
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35148Cell killing detected by BLI could also be verified at the
macroscopic level by visual comparison of brain sections from
control mice and those treated with therapeutic cells plus GCV
(Fig. 4C), and while sections from control mice brains showed a
clear tumor mass, those from mice inoculated with tumor plus
therapeutic cells and treated with GCV had a normal macroscopic
appearance and showed no signs of tumors.
Corroboration of BLI analysis was also provided by fluorescence
confocal microscope observation of mouse brain sections that
showed (Fig. 5) the presence of red fluorescent Rluc-R-tTK-
hAMSCs evenly distributed throughout the tumor implantation
site mixed with green fluorescent tumor cells, at T=0 before
starting GCV treatment (Fig. 5A). In well developed tumors
(T=49) from control group 1:4+PBS, red fluorescent Rluc-R-
tTK-hAMSCs could also be detected in clusters within the green
fluorescent mass of the well developed tumor (Fig. 5B). However,
brains from mice in the 1:4+GCV group had few detectable tumor
cells and no detectable Rluc-R-tTK-hAMSCs, in accordance with
the BLI analysis (Fig. 5C).
Post-engraftment survival of therapeutic hAMSCs
The fate of Rluc-R-tTK-hAMSCs was monitored by BLI at the
implantation day (T=26) and 6 days later (T=0), at the
beginning of GCV treatment (Fig. 4E). The number of detected
PHCs at T=0 corresponded with that produced by 1.5610
4 Rluc-
R-tTK-hAMSCs in standard plots (Fig. 2B), near to a 10 fold
decrease relative to T=26. However, due to their rapid
proliferation the amount of light produced by Pluc-G-U87 tumor
cells in the 1:4+GCV and 1:4+PBS groups, at T=0 corresponded
to approximately 2610
5 cells (Fig. 4E). Therefore, during the 6
days previous to GCV treatment, the ratio of PLuc-G-U87: Rluc-
R-tTK-hAMSCs changed by 52 fold, from 1:4 to 13:1. Thus, the
later is the actual ratio at which therapeutic effect is exerted.
Fate of tumor implanted Rluc-R-tTK-hAMSCs therapeutic
cells
In an attempt to understand the mechanism by which the Rluc-
R-tTK-hAMSCs+GCV treatment achieves the observed high
degree of therapeutic effect, the differentiation behavior of
Figure 3. In vivo optimization of tumor to therapeutic cell ratio. Tumor and therapeutic cells mixed in proportions 1:0, 1:1, 1:2 and 1:4 (Pluc-G-
U87:Rluc-R-tTK-hAMSC) were implanted in the brain of SCID mice and treated at day 6 i.p. with either GCV or PBS as indicated and monitored by BLI
at weekly intervals. (A) The graph shows in vivo changes in light production by Pluc expressing tumor cells resulting from GCV treatment. (B)
Histogram showing PHC values at the end of the experiment (T=35). Values were normalized relative to those at T=0 according to the formula [(T5/
T0)6100=tumor variation (%)]. Data are shown as mean 6 SEM, *P,0.05, compared to the 1:0+GCV group, n=5 for each group. (C) Representative
pseudo-color BLI images showing evolution of tumor size during treatment of animals inoculated with the indicated proportions of Pluc-G-U87 to
Rluc-R-tTK-hAMSC. Color bars represent light intensity levels from Pluc luciferase, ranging from low: blue to high: red. Luciferase images are
superimposed on black and white with images of the same mouse.
doi:10.1371/journal.pone.0035148.g003
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Rluc-R-tTK-hAMSCs and labeled them with a second Pluc-eGFP
reporter under transcriptional control by the PECAM/CD31
promoter, as a reporter of differentiation to the endothelial
lineage. With this strategy, changes in PECAM-regulated
luciferase expression could be quantitatively related to those of
the constitutively expressed Rluc, now an internal standard in the
same cell that allows the elimination of potential artifacts related to
Figure 4. In vivo BLI of hAMSC mediated tumor therapy. (A) Diagram illustrating experimental procedure. (B) Composite pseudo-color BLI
images from mice implanted with 4610
4 Pluc-G-U87 plus 1.6610
5 Rluc-R-tTK-hAMSCs and treated with GCV (1:4+GCV); 4610
4 Pluc-G-U87 plus
1.6610
5 Rluc-R-tTK-hAMSC and treated with PBS (1:0+GCV), and with 4610
4 Pluc-G-U87 only and treated with GCV. Images were acquired once per
week. (C) Representative images of brain sections at day 49. Top: brain of a 1:4+GCV treated mouse. Bottom: brain of a 1:0+GCV mouse, arrow points
to tumor area. (D) In vivo changes in light production by U87 tumors expressing Pluc, resulting from GCV treatment and tumor cell death. Light
values, calculated from the recorded images, are represented as log10 mean 6 SEM; n=8; * p,0.05, compared to the 1:0+GCV. (E) Representative
pseudo-color images from Rluc-R-tTK-hAMSC and Pluc-G-U87 at day of implantation, T=26 (1 and 3) and at initiation of GCV treatment, T=0 (2 and
4). Luciferase images are superimposed on black and white images of the same mouse. The included numerical values indicate the cell numbers
extrapolated from the ‘‘light vs cells’’ standard curve. Arbitrary color bars illustrate relative light intensities from PLuc and Rluc luciferases, lowest: blue
and black; highest: red and blue, respectively.
doi:10.1371/journal.pone.0035148.g004
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mixed with un-labeled U87 tumor cells and implanted at the
standard brain location. BLI analysis of Pluc and Rluc expression
at days 0 and 7 post-implantation showed (Fig. 6A) that while the
bulk of implanted hAMSCs disappears from the tumor during the
7 day period, cells expressing PECAM-promoter regulated Pluc
remained associated to the tumor. Moreover, the ratio of
PECAM/CD31 promoter-regulated Pluc activity to constitutive-
ly-expressed Rluc increased considerably by 92 fold, indicating
that a subpopulation of the implanted hAMSCs had differentiated
to the endothelial lineage and remained at the tumor site (Fig. 6B).
In addition, analysis by laser confocal microscopy of tumor
sections showed (Fig. 6C) that implanted cells expressing the RFP
and eGFP regulated by the PECAM/CD31 promoter were closely
associated to tumor microvascular structures and had endothelial
morphology. The endothelial lineage of therapeutic cells associ-
ation to vascular structures in the tumor was further verified by
perfusing some of the mice with a fluorescein-conjugated high
MW dextran not diffusible past the vascular endothelium.
Confocal microscope analysis of sections of the perfused tumors
showed the presence of RFP expressing therapeutic cells that
positively stained with an anti-human PECAM/CD31 antibody
and were closely associated to FITC-dextran labeled vascular
structures (Fig. 6D).
In this experiment all the implanted therapeutic cells express
RFP but only a fraction of them is induced to express the
endothelial lineage reporters. This double label strategy offered the
possibility of determining if the decrease in RLuc expressing
therapeutic cells previously observed in tumors could be due to
silencing of the CMV promoter that regulates RLuc, RFP and
tTK expression. To do this, tumor sections were also analyzed to
determine the proportion of eGFP expressing therapeutic cells that
did not express RFP. Our assessment showed that most of eGFP
expressing cells also expressed RFP and only 10% or less of the
eGFP expressing cells did not express RFP, ruling out CMV
promoter silencing as the cause for the decrease in production
RLuc. photons within tumors.
Implantation of Rluc-R-tTK-hAMSC directly on
established tumors also mediates bystander
glioblastoma therapy
To verify that the Rluc-R-tTK-hAMSC mediated therapeutic
approach is also effective under more clinical like conditions, 6
week old SCID mice were first stereotactically inoculated at the
previously indicated coordinates only with 4610
4 Pluc-G-U87
cells. Six days post implantation (T=0) one halve of the mice
randomly chosen (n=4) received an intracranial intratumoral
injection of 1.6610
5 Rluc-R-tTK-hAMSCs. On day three mice
were imaged by BLI to monitor Pluc-G-U87 tumor development,
following which GCV treatment was initiated consistent of a daily
dose of .GCV during a four week periods followed by 3 day rest
periods. Weekly BLI was used to monitor tumor development
during the experiment. On days 33 and 68, when the drop in
Renilla luciferase emission indicated the disappearance of
implanted Rluc-R-tTK-hAMSCs, additional intratumoral inocu-
lations of 1.6610
5 Rluc-R-tTK-hAMSCs were performed.
As shown in Fig. 7A, the administration of Rluc-R-tTK-
hAMSCs in combination with GCV results in the inhibition of
tumor growth. Moreover, the tendency of treated tumors to regain
growth when implanted therapeutic cells disappear is effectively
conteracted by repeated inoculation of additional Rluc-R-tTK-
hAMSC and GCV treatment. By day 53 right before all the
control mice had died, light produced by tumors treated with
therapeutic cells plus GCV was only 0,12% of that produced by
the control tumors. Kaplan-Meier survival graph (Fig. 7B) showed
that the treatment protocol resulted in significant (p,0.05)
increase in animal survival. Median survival was 88,5 d (treated
animals) and 51 d (control animals).
Discussion
In the current work we demonstrate a procedure to develop
therapeutic strategies against a human U87 glioblastomas and an
effective therapy model in SCID mice. The procedure is based on
the use of hAMSCs genetically modified to express the herpes
Simplex tTK as vehicles to deliver bystander toxicity to tumors.
To analyze the behavior of tumor and therapeutic cells, we labeled
the former with a CMV promoter regulated Pluc-eGFP chimerical
reporter, and the latter with a different trifunctional chimerical
reporter comprising Rluc-RFP and tTK activities [27]. This
approach allowed us to monitor the location and number of tumor
and therapeutic cells in live mice during treatment with GCV, and
optimize cell and prodrug treatment.
We established that both, tTK activity in genetically modified
hAMSCs, and administration of GCV were both required for
bystander killing of tumor cells co-cultivated with hAMSCs.
In vivo BLI of predetermined numbers of hAMSC and U87 cells,
stereotactically implanted at a specific site of the mouse brain,
allowed us to correlate the number of photon events recorded by
BLI with that of implanted cells, for their quantification during
therapy.
An optimum therapeutic ratio of 4 hAMSCs to 1 U87 cell was
empirically determined by implanting predetermined proportions
of both cell types in mouse brains and administering GCV i.p.
after a 6 day period, allowed for tumor establishment. Analysis of
hAMSC behavior during the 6 day pre-treatment period indicated
that a large proportion of the therapeutic cells disappeared, while
tumor cells proliferated. This lead to a 50 fold, reduction in the
proportion of therapeutic to tumor cells, that was 1:13 by the time
the GCV treatment began. This result not only emphasizes the
effectiveness of hAMSCs as therapeutic vehicles, but also suggests
Figure 5. Effect of GCV on fluorescent Rluc-R-tTK-hAMSC at tumor implantation sites. Left, representative images of HE stained brain
sections; Right, representative fluorescence confocal microscope images showing implanted red fluorescent cells Rluc-R-tTK-hAMSC (arrow), and
Pluc-G-U87 cells (green). (A) Control mouse (1:4+PBS) at T=0, (B) control mouse (1:4+PBS) at T=49, (C) treated mouse (1:4+GCV) at day 49. Blue,
Hoescht stained nuclei. Scale bar=10 mm.
doi:10.1371/journal.pone.0035148.g005
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likely improve even more the therapeutic outcome. The
disappearance of a large proportion of hAMSCs when injected
in immunosupressed mice has been previously observed [28].
However, the reduction in hAMSC number should not be
attributed to CMV promoter silencing. In a previous study by
Vilalta et al. [19], hAMSCs expressing Pluc regulated by the
constitutively active SV40 promoter also lost between 75–90% of
cells within the first 10 days post inoculation in SCID mice.
Moreover, since in our cell differentiation experiment all the
therapeutic cells are initially red fluorescent and become also
green fluorescent upon differentiation to the endothelial lineage,
silencing of the CMV promoter should result in the appearance of
green fluorescent cells that show no red fluorescence. Thus CMV
silencing can be evaluated by determining the proportion of
therapeutic cells expressing GFP (regulated by the inducible
PECAM/CD31 promoter) that do not express RFP (regulated by
the CMV promoter) in histological sections of tumors. While
extensive silencing of the CMV promoter would be required to
produce the 92 fold increase in PECAM/CD31-PLuc expression
Figure 6. Endothelial differentiation of hAMSCs in U87 tumors. Double transduced hAMSCs expressing PECAM-promoter regulated PLuc-
GFP and CMV-promoter regulated Rluc-R-tTK were mixed 4:1 with unlabelled U87 glioma cells, implanted in the brain of mice and imaged at the
indicated times. Mice were then inoculated with a 2,000,000 MW FITC-conjugated dextran and the brains harvested, fixed in formalin and prepared
for microscopy. (A) Representative BLI images showing Rluc (left) and Pluc (right) activities at T=0 (1 and 2) and T=7 (3 and 4), respectively. Pseudo
color images are superimposed on black and white dorsal images of recipient mice. Color bars illustrate relative light intensities of Pluc (right) and
Rluc (left); low: blue and black; high: red and blue, respectively. (B) Histograms showing the change in the ratio of Pluc/Rluc activities during the
indicated time period. Bars represent mean 6 SEM of photon counts recorded in BLI images. * p,0.05, n=4. (C) Representative laser confocal
microscope images of the corresponding brain tumor slices showing hAMSCs expressing CMV-promoter regulated RFP (red) and PECAM-promoter
regulated eGFP (green). Scale bar=20 mm. (D) FITC-stained microvessel (green), associated with red fluorescent hAMSCs (red), also labeled by an anti
human PECAM antibody (gray) Scale bar=25 mm.
doi:10.1371/journal.pone.0035148.g006
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10% of GFP positive cells that were not RFP positive. This result
excludes CMV promoter silencing, and pointing to cell death or
diffusion from the tumor sites as the likely causes for the drop in
RLuc production following cell implantation.
The therapeutic effectiveness of hAMSCs was evaluated by
comparing their capacity to inhibit U87 tumor growth by
implanting the optimal 4:1 (hAMSC to U87) proportion in mice
brains, and treating with GCV or PBS. Such experiments showed
that treatment with GCV of tumors containing hAMSCs reduced
the number of tumor cells by a factor of 10
4, relative to tumors
without hAMSCs, also treated with GCV, or tumors with
hAMSCs treated with PBS.
For the same tumor, by the end of the experiment, treatment
with hAMSCs plus GCV had reduced tumor cell number to
0,12% of that at T=0. However, in tumors without hAMSCs but
also treated with GCV tumor cell number increased by 319 fold in
the same period.
Macroscopic and laser confocal microscope examination of
brain slices at the end of experiments corroborated BLI imaging
results. While brains from mice with untreated mixed-cell tumors
had large tumor masses containing green and red fluorescent cells,
no macroscopic tumors and few green fluorescent cells were found
in the brains of mice implanted with tumors plus therapeutic cells
and treated with GCV.
In experiments better modeling a clinical situation, we show
that implantation of therapeutic hAMSCs on preestablished
glioblastoma U87 tumors and treatment with GCV also results
in tumor growth inhibition that lasts as long as there were
surviving therapeutic hAMSCs. Moreover, repeated inoculations
of therapeutic hAMSCs resulted in a progressive reduction of
tumor size and a significant extension of mice survival, relative to
untreated controls.
Insight on the therapeutic mechanism mediated by hAMSCs
was gained using a double label strategy that allows monitoring of
changes in gene expression on a ‘‘per cell’’ basis. This was
achieved by labeling of the same therapeutic cell that already
expressed Rluc-RFP reporter constitutively, with a different Pluc-
eGFP reporter regulated by the inducible human PECAM
promoter. By co-implanting these cells with unlabelled U87
tumors and monitoring by BLI we could observe that within the
first 7 days post implantation, a large proportion of the hAMSCs
disappeared from the tumor site, either by death or dispersion.
However, a subpopulation of the cells that expressed PECAM-
promoter regulated luciferase remained in close association with
the tumor. Moreover, in the tumor associated cell population, the
ratio of PECAM-regulated to CMV-regulated luciferase activity
increased with time reaching by day 7 a value 92 fold higher than
that at implantation time. This results indicated that tumor
associated hAMSCs were actively differentiating to the endothelial
Figure 7. Response of U87 tumors to direct implantation of therapeutic cells and GCV treatment. (A) In vivo changes in light production
by U87 tumors expressing Pluc, resulting from inoculation of Rluc-R-tTK-hAMSCs and GCV treatment. Dots represent PHCs values from individual
animals (T: Treated mice; C: Control mice). The bars represent the average values from each group. Arrows indicate the inoculation of Rluc-R-tTK-
hAMSCs. Light values, calculated from the recorded images, are represented as log10 of the mean 6 SEM; n=4; * p,0.05, compared to the control
group. (B) Kaplan-Meyer graph sumarizing mice survival following the above treatment. Median survival, treated mice, 88,5 d; control mice, 51 d,
p,0.05.
doi:10.1371/journal.pone.0035148.g007
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microscopy of tumor slices revealed RFP and eGFP expressing
hAMSCs with endothelial morphology in close association with
tumor vascular structures. This latter result was further corrob-
orated by positive staining of microvessel associated red fluorescent
hAMSCs with an anti human PECAM antibody.
Association of bone marrow derived MSCs with vascular
structures in tumors has been reported previously [29,30].
However, the vascular associated cells were shown to express
pericyte specific antigens while PECAM/CD31 is considered an
endothelial specific marker. Both findings are not mutually
exclusive, and in the absence of additional data, could be
reconciled by considering that differentiation of mesenchymal
stromal cells may depend on their tissue of origin as well as on the
specific tumor environment in which they are implanted [31]. Our
results suggest that GCV induced suicide of hAMSCs not only kills
neighboring tumor cells by bystander effect but also by eliminating
the associated vascular system that supplies oxygen and nutrients.
In conclusion, we demonstrate a general and versatile strategy
to develop cell based tumor therapies and evaluate their
effectiveness based on the use of chimeric bioluminescent and
fluorescent reporters introduced in tumor and therapeutic cells,
followed by analysis of their behavior by non invasive real time
BLI and confocal microscopy.
With this strategy we were able to show that tTK expressing
hAMSCs are very effective vehicles to deliver localized cytotoxic
therapy to U87 glioblastomas and that hAMSCs within tumors
differentiate to endothelial lineage cells that associate with vascular
structures. Implantation of genetically modified hAMSCs may
provide an effective procedure to eliminate residual tumor cells in
surgical borders after tumor removal.
In future research we will use the above strategy to improve the
preclinical significance of the therapy model. We will focus on
evaluating procedures for therapeutic cell delivery, including the
use of a biomaterial to protect and control the delivery of
therapeutic cells implanted in tumors. To evaluate the relevance of
the immune environment on the therapeutic effectiveness, we will
use immune-competent mice implanted with singeneic glioma
tumor model that will be treated with autologous therapeutic
hAMSCs. Finally, we will seek to validate the generality of the
therapeutic procedure using glioma tumors from human biopsies
implanted in immunedefficient mice.
Materials and Methods
Vector constructs
Three lentiviral vectors constructs were used to label cells. hrl-
mrfp-tk vector contains a chimeric trifunctional reporter compris-
ing Rluc, monomeric red fluorescent protein (mRFP1) and a
truncated version of the herpes simplex virus thymidine kinase
coding sequences (sr39tk) regulated by the Cytomegalovirus
promoter, was constructed [27]. pRRL-Luc-IRES-EGFP vector,
containing the PLuc under control of the cytomegalovirus (CMV)
promoter followed by an IRES to express an eGFP, was a kind
donation from L. Alvarez-Vallina [32]. pLox:Pecam-Luc:eGFP
vector that expresses chimeric Pluc and eGFP regulated by the
endothelial specific promoter PECAM was constructed in our
group. Lentiviral vector containing a fusion reporter comprising
PLuc and eGFP, was obtained by polymerase chain reaction
amplification and standard cloning procedures using the Pluc and
eGFP genes from plasmid pGL4.10:PLuc (Promega Corporation,
Madison, WI, USA) and pEGFP-N1 plasmid (Clontech Lab., Palo
Alto, CA, USA). hPECAMp was kindly provided by Dr. Carmelo
Bernabe ´u.
Lentiviral particle production
Production of viral particles was performed using human
embryonic kidney cells 293T (ATCC, CRL-11268
TM) grown in
Dulbecco’s Modified Eagle’s Medium-high glucose (DMEM-hg)
(Sigma, Steinheim, Germany), 10% heat-inactivated fetal bovine
serum (FBS) (Sigma), 2 mM L-glutamine (Sigma), 50 units/ml
penicillin/streptomycin (Sigma), and 2 mM HEPES. The day
previous to transfection, 3610
6 cells were seeded on 10 cm
2 poly-
D-lysine (Sigma) treated plates. 6 mg of each lentiviral transfer
vector, were mixed with 2 mg of viral envelope plasmid (pMD-G-
VSV-G) and 4 mg of packaging construct (pCMV DR8.2) in
250 ml of 150 mM NaCl and then mixed with 48 ml of 1 mg/ml
polyethylene amine (Polyscience, Warrington, PA, US) in 250 ml
of 150 mM NaCl, and incubated at room temperature (RT) for
20 min. This DNA solution was then added drop wise to the plate
containing the 293T cells plus medium, swirled gently and
incubated for 16 h at 37uC with 5% CO2. The following day, the
transfection solution was removed, the cells were rinsed with PBS
1X and medium without FBS was added to the cells. Following a
48 h incubation the supernatant was collected, centrifuged at
2000 rpm to remove cell debris, and filtered through a 0,45 mm
low protein binding filter (Corning, Bath, UK).
Cell lines and cell culture
hAMSCs were isolated from adipose tissue derived from
cosmetic subdermal liposuctions, with patient consent, as de-
scribed previously [26]. Liposuction samples were obtained after
written informed consent by anonymous donors from Hospital de
la Santa Creu i Sant Pau, Barcelona, Spain. Work with human
samples was approved by written consent by the Ethical
Committee of Clinical Investigation of Hospital Santa Creu i
Sant Pau, Barcelona, Spain; and Bioethical Subcommittee of
Superior Council of Scientific Research. Briefly, lipoaspirate was
suspended in 1X collagenase type I (Invitrogen, Carlsbad, CA)
solution and incubated at 37uC and inactivated by addition of
DMEM+10% FBS. hAMSC were isolated by plastic adherence
technique. hAMSCs were grown in DMEM-hg with 20% FBS
(Hyclone, Logan, UT), 2 mM L-glutamine (Sigma) and 50 units/
ml penicillin/strepotomycin (Sigma), expanded for until 70% of
confluence and infected with either the hrl-mrfp-tk, or with both,
first with the hrl-mrfp-tk and then with the pLox:Pecam-Luc:eGFP
viral vector stocks, using 10 mg/ml polybrene (Sigma) and
incubated for 24 to 48 hours (MOI=20). Human glioma cells
U87 (ATCC, HTB-14), were grown in nutrient mixture DMEM/
Hams F12 HAM containing 10% heat-inactivated FBS (Sigma),
2 mM L-glutamine (Sigma) and 50units/ml penicillin/strepoto-
mycin (Sigma). U87 were infected, as described, with pRRL-Pluc-
IRES-eGFP viral stock (MOI=20) to obtain Pluc-G-U87, as
described above. Expression of fluorescent proteins was used to
select positively transduced cells.
Cell proliferation assays
Quadruplicates of 3610
3 Rluc-R-tTK-hAMSC or untrans-
duced hAMSCs an 5610
3 Pluc-G-U87 cells were plated into 96-
well plates and incubated overnight at 37uC. Culture medium was
replaced with medium containing 4 mg/ml GCV 24 h later
(T=0). Cell proliferation was evaluated spectrophotometrically at
490 nm, using the CellTiter 96 Aqueous One Solution Cell
Proliferation Assay (Promega) at days 0, 5 and 9. Results were
expressed as the percentage of proliferation, where the prolifer-
ation of cells in culture medium at day 0 was set to 100%. Mixed
cell cultures containing 10
4 Pluc-G-U87 with several proportions
of Rluc-R-tTK-hAMSC were seeded on 48-well plates and
analyzed by BLI at days 0 (the onset of GCV treatment), 5 and
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every 3 days.
BLI determination of luciferase activity
In vitro cultures. For BLI of tissue culture plates, medium
was removed from the wells, the wells were rinsed twice with PBS
16, and imaged immediately following addition of 100 ml/well of
Pluc or Rluc substrate stock reagent (Caliper, Hopkinton, MA, US
and Prolume, Pinetop, AZ, US). Imaging of PLuc and Rluc
activities was performed in consecutive days.
For imaging, plates are placed in the detection chamber of a
high-efficiency ORCA-2BT Imaging System (Hamamtsu Photon-
ics, Hamamatsu City, Japan) provided with a C4742-98-LWG-
MOD camera fitted with a 5126512 pixel charge couple device
(CCD) cooled at 280uC. Images were acquired during 1 min
using 161 array (binning 161), and in order to register the
position of the light signal, an additional image was obtained using
a white light from a lamp in the detection chamber. Light events
were calculated using the Wasabi image analysis software and
expressed as PHC after discounting the background of wells
without cells. The net number of PHCs in the area of interest was
calculated using the formula: PHCs=(total number of PHCs in
the area of interest)2[(number of pixels in the area of
interest)6(average background PHCs per pixel)].
Pseudo color images were generated using arbitrary color bars
representing standard light intensity levels for Pluc (blue: lowest;
red: highest) and for Rluc (black: lowest; blue: highest).
In vivo bioluminescent imaging. In vivo BLI of engrafted
SCID mice was performed as described previously [26]. Briefly,
mice were anesthetized i.p. and then injected i.p. with 150 mlo f
luciferin (Caliper) (16.7 mg/ml in saline) or through tail vein with
25 ml of benzyl coelenterazine (1 mg/ml in 50/50 propilenglycol/
ethanol) (Prolume) diluted in 125 ml of water. When BLI was
performed after the surgery no anesthesia was required. Animals
were placed in the detection chamber of the high efficiency
ORCA-2BT Imaging System and images acquired from the dorsal
direction during a 5 min period. A second image of the animal was
obtained using a white-light source inside the detection chamber,
to register the position of the luminescence signal. To increase
detection sensitivity, the readout noise of the recorded signal was
reduced by adding together the light events registered by arrays of
868 adjacent pixels that are read simultaneously (binning 868) of
the camera CCD. Mice were imaged weekly during experiments.
Quantification and analysis of photons recorded in images was
done using the Wasabi image analysis software (Hamamatsu
Photonics) as described above.
In order to establish the correlation between the number of
transplanted cells and the amount of emitted light, standard curves










Rluc expressing cells, stereotactically injected in the brain (0.6 mm
posterior, 2 mm lateral and 2.75 mm depth respect bregma). Light
measurements were expressed as PHCs following subtraction of
background as previously described. Data were represented as the
number of PHCs versus number of grafted cells.
Animal experiments
Adult 6–8 weeks old SCID mice were purchased from (Charles
Rivers, Wilmington, MA, USA) and kept under pathogen-free
conditions in laminar flow boxes. Animal maintenance and
experiments were performed in accordance with established
guidelines of Catalan Government and protocol num. 4565
approved by Direccio ´ General del Medi Natural, Generalitat de
Catalunya. Animals were anesthetized by i.p. injections of xylazine
(Henry Schein, Melville, NY,USA) 3.3 mg/kg and ketamine
(Merial, Duluth, GA, USA) 100 mg/kg. Subsequently mice were
mounted in a stereotactic frame (Stoelting, Wood Dale, IL,
U.S.A.) and their heads were secured using a nose clamp and two
ear bars, and a skin flap was lifted to expose the skull surface and
further anesthetized, by injection of fentanil (Kernpharma,
Barcelona, Spain). For stereotactic cell implantation, a burr hole
was drilled and the cell suspensions was injected at a 250 nl/min
rate using a Hamilton syringe series 700 at the previously indicated
coordinates. The injections were delivered at a rate of 0.25 ml/
min, and the needle was slowly withdrawn after an additional
5 minutes. The scalp was closed by suture and the animals were
placed in individual recovery cages and supplied with buprenor-
fine (Buprex, Schering Plough SA, Madrid, Spain) in the drinking
water. GCV sodium (Cymevene, Roche, Basel, Switzerland) was
injected i.p. daily at a dose of 100 mg/kg [33,34].Control animals
were inoculated with the same volume of PBS.
Histology
Brain from sacrificed mice were harvested, washed with
physiological serum and fixed with paraformaldehyde during
48 hours. Brains were then washed with PBS 16, embedded in
OCT, sliced in 20 mm sections and mounted on glass slides.
Hoechst staining was performed for detection of cell nuclei. For
macroscopic view analysis 20 mm brain sections were stained with
Hematoxylin and Eosin (HE). Immunohistochemical detection of
endothelial cells was performed on 10 mm thick section using a
primary hPECAM-1 (4 mg/ml) (Abcam, Cambridge, UK).
Secondary antibody conjugated with Cy5 (3 mg/ml) (Jackson
ImmunoResearch, Suffolk, UK) was applied and sections
counterstained with Bisbenzimide (Hoechst, Sigma).
Fluorescence angiography and Laser Confocal
microscope observation of brain implanted hAMSCs
For tumor microvessel imaging, mice were anesthetized and
injected trough the lateral tail vein with 200 ml (10 mg/ml) of a
high molecular weight (2,000,000 MW) FITC-conjugated dextran
Sigma (St Louis, MO, US). Ten minutes after the injection mice
were sacrificed and brains were retrieved and fixed in formalin
solution 10% (Sigma) during 24 hours. The fixed brains were
sliced and analyzed for microvessel formation and presence of
fluorescent hAMSCs using confocal laser scanning microscopy
(Leica TS1 SP2).
Flow citometry. Supporting file Methods S1.
Statistical analysis
Student’s unpaired two-tailed t-test was used for comparison
between groups. Descriptive statistics were performed with SPSS
Statistics (15.0.1 version, SPSS Inc., Chicago, IL). Data are
presented as mean 6 SEM and considered significant at p,0.05
or p,0.01.
Supporting Information
Figure S1 Characterisation of transduced and untrans-
duced hAMSC. (A) Flow cytometric analysis of hAMSCs (top)
and RLuc-R-tTK-hAMSCs (below) using antibodies against CD
105, CD44, CD29, CD90, CD73, CD106, CD34, CD45 showed
no difference in marker expression. (B) Proliferation rate of
transduced and untransduced MSCs was evaluated spectrophoto-
metrically by standard 3-(4-5-dimethyl-2-yl)-5-(3-carboxymethox-
yphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt (MTS) assay and
expressed as percentage of cell proliferation (respect day 0).
(TIF)
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hAMSC and U87 were cultured in medium containing GCV at
indicated concentrations (0 mg/ml, 2 mg/ml, 4 mg/ml and 8 mg/
ml). Cell viability was evaluated spectrophotometrically by
standard MTS assay and expressed as percentage of cell
proliferation (respect day 0) * P,0,001 n=4 for each group. (A)
RLuc-R-tTK-hAMSC proliferation rate is sensitive to GCV dose.
At day 5 there is a linear correlation between GCV concentration
and cell death. (B,C) hAMSCs and U87 proliferate without
significant change even in the presence of high concentrations of
GCV confirming its low toxicity.
(TIF)
Figure S3 In vivo monitorization of tumor progression
in hAMSCs mediated therapy. Pseudo-color images from
1:4+GCV (A), 1:4+PBS (B) and 1:0+GCV (C) groups were
acquired once per week. Luciferase images are superimposed on
black and white with images of the same mouse. U: tumor
unrelated death; T: tumor related death.
(TIF)
Methods S1 Flow cytometry analysis of hAMSC mark-
ers. hAMSC and RLuc-R-tTK-hAMSC suspended in phosphate-
buffered saline plus 1% bovine serum albumin and incubated with
mouse anti-human cd90-PE (BD Bioscience); mouse anti-human
cd34-PE (ab-cam); mouse anti-human cd105-PE (BD Bioscience);
mouse anti human cd 106-PE (BD, Bioscience); mouse anti-human
cd73-PE (BD, Bioscience); mouse anti-human cd29 (BD, Biosci-
ence); mouse anti-human cd45-FITC (BD, Bioscience); mouse anti-
human cd44-PE(BD, Bioscience).Unspecific binding was assessed
by isotype control mouse IgG2a-PE (BD, Biosciences), mouse
IgG1k-PE (BD, Bioscience) and mouse IgG1k-FITC (BD, Biosci-





We thank Dr. Carmelo Bernabeu (Centro de Investigaciones Biolo ´gicas,
High Council of Scientific Investigations, Spain) for the kind donation of
PECAM-1 promoter; Dr. Esther Pen ˜a (Head of Confocal Microscopy) for
excellent technical assistance.
Author Contributions
Conceived and designed the experiments: JB MA NR JRB JM SSG.
Performed the experiments: MA JRB EA CS. Analyzed the data: MA JB
NR OFV JM. Contributed reagents/materials/analysis tools: MA OFV JB
JM. Wrote the paper: MA JB NR SSG.
References
1. Schneider T, Mawrin C, Scherlach C, Skalej M, Firsching R (2010) Gliomas in
adults. Dtsch Arztebl Int 107: 799–807; quiz 808.
2. Buckner JC, Brown PD, O’Neill BP, Meyer FB, Wetmore CJ, et al. (2007)
Central nervous system tumors. Mayo Clin Proc 82: 1271–1286.
3. Argyriou AA, Kalofonos HP (2009) Molecularly targeted therapies for malignant
gliomas. Mol Med 15: 115–122.
4. Aboody KS, Najbauer J, Danks MK (2008) Stem and progenitor cell-mediated
tumor selective gene therapy. Gene Ther 15: 739–752.
5. Dasari VR, Velpula KK, Kaur K, Fassett D, Klopfenstein JD, et al. (2010) Cord
blood stem cell-mediated induction of apoptosis in glioma downregulates X-
linked inhibitor of apoptosis protein (XIAP). PLoS One 5: e11813.
6. Oertel S, Krempien R, Lindel K, Zabel A, Milker-Zabel S, et al. (2006) Human
glioblastoma and carcinoma xenograft tumors treated by combined radiation
and imatinib (Gleevec). Strahlenther Onkol 182: 400–407.
7. Menon LG, Kelly K, Yang HW, Kim SK, Black PM, et al. (2009) Human bone
marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular
delivery vehicle for human glioma therapy. Stem Cells 27: 2320–2330.
8. Ehtesham M, Kabos P, Kabosova A, Neuman T, Black KL, et al. (2002) The
use of interleukin 12-secreting neural stem cells for the treatment of intracranial
glioma. Cancer Res 62: 5657–5663.
9. Benedetti S, Pirola B, Pollo B, Magrassi L, Bruzzone MG, et al. (2000) Gene
therapy of experimental brain tumors using neural progenitor cells. Nat Med 6:
447–450.
10. Prockop DJ (1997) Marrow stromal cells as stem cells for nonhematopoietic
tissues. Science 276: 71–74.
11. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, et al. (1999)
Multilineage potential of adult human mesenchymal stem cells. Science 284:
143–147.
12. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, et al. (2001) Multilineage cells
from human adipose tissue: implications for cell-based therapies. Tissue Eng 7:
211–228.
13. Kucerova L, Altanerova V, Matuskova M, Tyciakova S, Altaner C (2007)
Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer
gene therapy. Cancer Res 67: 6304–6313.
14. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, et al. (2005) Human
bone marrow-derived mesenchymal stem cells in the treatment of gliomas.
Cancer Res 65: 3307–3318.
15. Hamada H, Kobune M, Nakamura K, Kawano Y, Kato K, et al. (2005)
Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy.
Cancer Sci 96: 149–156.
16. Hall B, Dembinski J, Sasser AK, Studeny M, Andreeff M, et al. (2007)
Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based
delivery vehicles. Int J Hematol 86: 8–16.
17. Reiser J, Zhang XY, Hemenway CS, Mondal D, Pradhan L, et al. (2005)
Potential of mesenchymal stem cells in gene therapy approaches for inherited
and acquired diseases. Expert Opin Biol Ther 5: 1571–1584.
18. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, et al. (2003)
Immunosuppressive effect of mesenchymal stem cells favors tumor growth in
allogeneic animals. Blood 102: 3837–3844.
19. Vilalta M, Degano IR, Bago J, Gould D, Santos M, et al. (2008) Biodistribution,
long-term survival, and safety of human adipose tissue-derived mesenchymal
stem cells transplanted in nude mice by high sensitivity non-invasive
bioluminescence imaging. Stem Cells Dev 17: 993–1003.
20. Altanerova V, Cihova M, Babic M, Rychly B, Ondicova K, et al. (2011) Human
adipose tissue-derived mesenchymal stem cells expressing yeast cytosinedeami-
nase::uracil phosphoribosyltransferase inhibit intracerebral rat glioblastoma.
Int J Cancer.
21. Altaner C (2008) Prodrug cancer gene therapy. Cancer Lett 270: 191–201.
22. Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann JL, et al. (1993)
Regression of established macroscopic liver metastases after in situ transduction
of a suicide gene. Proc Natl Acad Sci U S A 90: 7024–7028.
23. Sangro B, Mazzolini G, Ruiz M, Ruiz J, Quiroga J, et al. (2010) A phase I
clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular
carcinoma. Cancer Gene Ther 17: 837–843.
24. Huang Q, Pu P, Xia Z, You Y (2007) Exogenous wt-p53 enhances the antitumor
effect of HSV-TK/GCV on C6 glioma cells. J Neurooncol 82: 239–248.
25. Moolten FL (1986) Tumor chemosensitivity conferred by inserted herpes
thymidine kinase genes: paradigm for a prospective cancer control strategy.
Cancer Res 46: 5276–5281.
26. Vilalta M, Degano IR, Bago J, Aguilar E, Gambhir SS, et al. (2009) Human
adipose tissue-derived mesenchymal stromal cells as vehicles for tumor bystander
effect: a model based on bioluminescence imaging. Gene Ther 16: 547–557.
27. Ray P, De A, Min JJ, Tsien RY, Gambhir SS (2004) Imaging tri-fusion
multimodality reporter gene expression in living subjects. Cancer Res 64:
1323–1330.
28. van der Bogt KE, Schrepfer S, Yu J, Sheikh AY, Hoyt G, et al. (2009)
Comparison of transplantation of adipose tissue- and bone marrow-derived
mesenchymal stem cells in the infarcted heart. Transplantation 87: 642–652.
29. Bexell D, Gunnarsson S, Tormin A, Darabi A, Gisselsson D, et al. (2009) Bone
marrow multipotent mesenchymal stroma cells act as pericyte-like migratory
vehicles in experimental gliomas. Mol Ther 17: 183–190.
30. Bexell D, Scheding S, Bengzon J (2010) Toward brain tumor gene therapy using
multipotent mesenchymal stromal cell vectors. Mol Ther 18: 1067–1075.
31. Nakanishi C, Nagaya N, Ohnishi S, Yamahara K, Takabatake S, et al. (2011)
Gene and Protein Expression Analysis of Mesenchymal Stem Cells Derived
From Rat Adipose Tissue and Bone Marrow. Circ J.
32. Sanz L, Santos-Valle P, Alonso-Camino V, Salas C, Serrano A, et al. (2008)
Long-term in vivo imaging of human angiogenesis: critical role of bone marrow-
derived mesenchymal stem cells for the generation of durable blood vessels.
Microvasc Res 75: 308–314.
33. Carroll NM, Chase M, Chiocca EA, Tanabe KK (1997) The effect of
ganciclovir on herpes simplex virus-mediated oncolysis. J Surg Res 69: 413–417.
34. Marconi P, Tamura M, Moriuchi S, Krisky DM, Niranjan A, et al. (2000)
Connexin 43-enhanced suicide gene therapy using herpesviral vectors. Mol Ther
1: 71–81.
Bioluminiscence Imaging for Glioma Cell Therapy
PLoS ONE | www.plosone.org 11 April 2012 | Volume 7 | Issue 4 | e35148